Acute Effect of Empagliflozin vs Dapagliflozin Over Pulse Wave Velocity in Type Two Diabetes

Diabetes Mellitus Type 2 Without Complication Clinical Trial

Official title: Acute Effect of Empagliflozin vs Dapagliflozin vs Placebo Administration Over Pulse Wave Velocity in Patients With Type Two Diabetes

Status Active, not recruiting

Clinical Trial Summary

To date one of the main independent biomarkers of cardiovascular disease is the arterial stiffness parameters measured by carotid-femoral pulse wave velocity. It is known that SGLT2 inhibitors develop cardiac protection over long term administration, but there's not enough studies about acute effects in early administration.

Clinical Trial Description

Measure basal carotid-femoral Pulse Wave Velocity through a Pulse Pen tonometer by DiaTecne among basic physical examination, blood test, anthropometric and hemodynamic measurements; then administrate randomly dapagliflozin 10 mg, empagliflozin 25 mg or placebo for 7 days and then perform all of the measurements and blood test again. ;

Related Conditions & MeSH terms

• Diabetes Mellitus
• Diabetes Mellitus Type 2 Without Complication
• Diabetes Mellitus, Type 2

• NCT number: NCT05109949
• Study type: Interventional
• Source: Centro Universitario de Ciencias de la Salud, Mexico
• Status: Active, not recruiting
• Phase: Phase 3
• Start date: March 30, 2020
• Completion date: August 1, 2022